A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab
Sign Up to like & getrecommendations! Published in 2023 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abq5068
Abstract: Immunogenicity against intravitreally administered brolucizumab has been previously described and associated with cases of severe intraocular inflammation, including retinal vasculitis/retinal vascular occlusion (RV/RO). The presence of antidrug antibodies (ADAs) in these patients led to the… read more here.
Keywords: pharmacology; immune complexes; immunogenicity; mechanistic drivers ... See more keywords